Galapagos completes acquisition of drug discovery service operations of Discovery Partners International

Mechelen, Belgium; 6 July 2006 – Galapagos NV (Euronext & LSE: GLPG), an integrated drug discovery company, announced today closure on the acquisition of all the drug discovery operations of Discovery Partners International (DPI) for €4.25 million in cash.  With this, the acquired assets of DPI have now become an integral part of Galapagos’ service division BioFocus DPI.
Galapagos acquired the operational activities of DPI as part of its strategy to become a worldwide leader in drug discovery services, ranging from target discovery to the delivery of candidate drugs.  The acquired operations include DPI’s drug discovery services sites San Diego and South San Francisco (USA), Basel (Switzerland) and Heidelberg (Germany) as well as DPI’s Japanese sales office in Tokyo.  These operations strengthen and broaden the BioFocus product offering and global presence, propelling the new BioFocus DPI group to a Top 5 position worldwide in the drug discovery market.  The acquisition also provides Galapagos with additional capacity to deliver on its broad drug discovery and development alliance in osteoarthritis with GlaxoSmithKline, announced in June 2006.  Based on this acquisition, Galapagos has increased its revenue guidance for 2006 from €25-30 million to €33-38 million.
About Galapagos
Galapagos is a publicly traded, genomics-based drug discovery company (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA, London AiM: GLPG) that has drug discovery programs based on proprietary, novel targets in bone and joint diseases – osteoarthritis, osteoporosis and rheumatoid arthritis.  Galapagos offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies through its division BioFocus DPI, encompassing target discovery and drug discovery services through to delivery of pre-clinical candidates.  In addition, BioFocus DPI provides adenoviral reagents for rapid identification and validation of novel drug targets and compound libraries for drug screening.  Galapagos currently employs more than 320 people, including 144 PhDs, and operates facilities in seven countries, with global headquarters in Mechelen, Belgium.  More information about Galapagos and BioFocus DPI can be found at
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 290 980 28
This press release may contain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continues” as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.